Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Jiangsu Recbio Technology Co., Ltd. Class H ( (HK:2179) ) has provided an update.
Jiangsu Recbio Technology Co., Ltd. has announced its participation in the H Share Full Circulation Plan, aiming to convert 141,953,490 unlisted shares into H shares. This strategic move is expected to significantly increase the company’s H share count to 94.85% of its total share capital, enhancing liquidity and potentially strengthening its market position on the Hong Kong Stock Exchange.
More about Jiangsu Recbio Technology Co., Ltd. Class H
Jiangsu Recbio Technology Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating within the biotechnology sector. The company is focused on developing and commercializing innovative vaccines and related technologies, with a market focus on expanding its share circulation and enhancing its presence on the Hong Kong Stock Exchange.
Average Trading Volume: 106,826
Technical Sentiment Signal: Buy
Current Market Cap: HK$4.4B
For an in-depth examination of 2179 stock, go to TipRanks’ Stock Analysis page.